Related Experiment Video

Updated: May 3, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

891

[Ten-day sequential therapy for Helicobacter pylori eradication in children: a systematic review of randomized

Ji-dong He1, Li Liu1, Yu-jiang Zhu1

  • 1Department of Gastroenterology, Second Municipal People's Hospital, Ya'an 625000, China.

Zhonghua Yi Xue Za Zhi
|February 14, 2014
PubMed

Insights

This study found that 10-day sequential therapy is an effective and safe treatment for Helicobacter pylori infections in children. It shows higher eradication rates compared to standard triple therapies, with similar adverse event profiles.

Area of Science:

  • Pediatric Gastroenterology
  • Infectious Diseases
  • Pharmacotherapy

Background:

  • Helicobacter pylori (H. pylori) infection is a significant cause of gastrointestinal issues in children.
  • Standard triple therapy regimens have varying efficacy and can lead to resistance.
  • Novel treatment strategies are needed to improve H. pylori eradication rates in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy and safety of a 10-day sequential therapy for H. pylori eradication in pediatric patients.
  • To compare the effectiveness of 10-day sequential therapy against standard triple therapy durations (7-day, 10-day, and 14-day).

Main Methods:

  • A systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) were conducted.
  • Searches included multiple databases (CENTRAL, Medline, Embase, CBMDisc, CNKI, VIP, WANFANG) from 2000-2013.
  • Fifteen trials involving 1348 children were analyzed to assess H. pylori eradication rates and adverse events.

Main Results:

  • 10-day sequential therapy demonstrated superior H. pylori eradication rates compared to standard triple therapy (80.78% vs. 69.84%, OR 2.13).
  • It was also more effective than 7-day and 10-day standard triple therapies (OR 2.23 and 2.11, respectively).
  • No significant difference in eradication rates was observed compared to 14-day standard triple therapy (OR 1.87). Adverse event rates were similar across regimens.

Conclusions:

  • 10-day sequential therapy presents a promising and safe alternative for treating H. pylori infections in children.
  • This regimen offers improved efficacy over shorter standard triple therapies.
  • Further research may solidify its role as a new standard of care in pediatric H. pylori treatment.
Abstract

More Related Videos

Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis04:56

Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis

Published on: May 16, 2025

1.5K
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.6K

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.5K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
807
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
1.0K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408